Mannosylated liposomes improve therapeutic effects of paclitaxel in colon cancer models. (18th August 2017)

• Record Type: Journal Article
• Authors: Xiong, Menghua; Lei, Qian; You, Xinyu; Gao, Tiantao; Song, Xuejiao; Xia, Yong; Ye, Tinghong; Zhang, Lidan; Wang, Ningyu; Yu, Luoting
• Is Part Of: Journal of microencapsulation. Volume 34:Number 6(2017)
• Page Start: 513
• Page End: 521
• Publication Date: 2017-08-18
• Subjects: Liposomes -- modified liposomes -- targeted drug delivery -- colon cancer -- mannose receptor; Microencapsulation -- Periodicals; Controlled release technology -- Periodicals; 615.19
• DOI: 10.1080/02652048.2017.1339739
• Languages: English
• ISSNs: 0265-2048

Abstract

Abstract: Mannose receptor (MR) is a highly effective endocytic receptor. It is closely related to tumour immune escape and metastasis. We found that MR was highly expressed in some colon cancer cell lines such as CT26 and HCT116 cells. Therefore, MR might be a potential target in colon cancer therapy. In this study, we aimed to develop mannosylated liposomes containing anticancer drug paclitaxel and investigate the potential effects on targeted therapy for colon cancer. Mannosylated liposomes were prepared by film dispersion method. Characterisation, drug release behaviour, cytotoxicity, cellular uptake, anti-tumour efficacy and safety profiles of liposomes were investigated. The results showed that mannosylated liposomes had a higher CT26 cells uptake efficiency and tumour inhibition rate, which might be due to the target effect to MR. And no notable toxicity was observed. Taken together, these data demonstrated that mannosylated liposomes could target colon cancer and improve the efficacy of chemotherapy.